Several antiphospholipid antibody (aPL) profiles (“triple” and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardiolipin antibody (aCL) and anti-β2 glycoprotein-I antibody (aβ2GPI), and with aPL persistence. Given that the 3 aPL tests detect partially overlapping sets of antibodies, the primary goal of this study was to characterize the associations among aPL tests using AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) core laboratory data. The APS ACTION Registry includes annually followed adult patients with positive aPL based on the Revised Sapporo Classification Criteria. We analyzed baseline and prospective core laboratory data of the registry for associations among aPL tests using the Spearman rank correlation with Bonferroni-adjusted significance level for multiple comparisons. An aPL Load was calculated based on 6 tests (aCL IgG/IgM/IgA and aβ2GPI IgG/IgM/IgA); a receiver operating characteristic curve was used to evaluate the diagnostic performance of the aPL Load in predicting LA positivity. In 351 patients simultaneously tested for LA, aCL, and aβ2GPI, the frequency of moderate-to-high (≥40 U) titers of aCL and aβ2GPI IgG/IgM/IgA was higher in patients who were positive for LA vs those who were negative. An aPL Load was calculated for each patient to assess the overall aPL burden. For every 1-point increase in the aPL Load, the possibility of a positive LA test increased by 32% (odds ratio, 1.32; 95% CI, 1.2-1.5; P <.001). Based on core laboratory data from a large international registry, most aPL enzyme-linked immunosorbent assay ≥40 U and a high calculated aPL Load combining 6 aPL enzyme-linked immunosorbent assays were predictive of a positive LA. These data suggest that the combined quantitative burden of aPL may provide a mechanistic explanation of a positive LA.

Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study / E. Gkrouzman, R. Willis, D. Andrade, M.G. Tektonidou, V. Pengo, G. Ruiz-Irastorza, H.M. Belmont, P.R. Fortin, M. Gerosa, F. Signorelli, T. Atsumi, D.W. Branch, C. Nalli, E. Rodriguez-Almaraz, M.A. Petri, R. Cervera, J.S. Knight, M. Efthymiou, H. Cohen, M.L. Bertolaccini, D. Erkan, R. Roubey, G. Pons-Estel, B. Giannakopoulos, S. Krilis, G. De Jesus, R. Levy, F. Signorelli, D. Andrade, G. Balbi, A.E. Clarke, L. Skeith, P.R. Fortin, L. Ji, Z. Zhang, C. Yang, H. Shi, S. Zuily, D. Wahl, M.G. Tektonidou, C. Nalli, L. Andreoli, A. Tincani, C.B. Chighizola, M. Gerosa, P. Meroni, V. Pengo, C. Cheng, G. Pazzola, S. Sciascia, S. Foddai, M. Radin, S. Davis, O. Amengual, T. Atsumi, I. Uthman, M. Limper, P.D. Groot, G. Ruiz—irastorza, A. Ugarte, I. Rodriguez-Pinto, R. Cervera, J. Pardos-Gea, E. Rodriguez Almaraz, M.J. Cuadrado, M.A. Aguirre Zamorano, C. Lopez-Pedrera, B. Artim-Esen, M. Inanc, M.L. Bertolaccini, H. Cohen, M. Efthymiou, M. Khamashta, I. Mackie, G. Sanna, J. Knight, Y. Zuo, M. Petri, R.K. Leaf, R. Roubey, T. Ortel, E. Gonzalez, R. Willis, N. Kello, M. Belmont, S. Levine, J. Rand, M. Barbhaiya, D. Erkan, J. Salmon, M. Lockshin, A.A. Duarte Garcia, D.W. Branch. - In: LABORATORY INVESTIGATION. - ISSN 0023-6837. - 103:6(2023 Jun), pp. 100147.1-100147.6. [10.1016/j.labinv.2023.100147]

Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

M. Gerosa;C.B. Chighizola;M. Gerosa;P. Meroni;
2023

Abstract

Several antiphospholipid antibody (aPL) profiles (“triple” and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardiolipin antibody (aCL) and anti-β2 glycoprotein-I antibody (aβ2GPI), and with aPL persistence. Given that the 3 aPL tests detect partially overlapping sets of antibodies, the primary goal of this study was to characterize the associations among aPL tests using AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) core laboratory data. The APS ACTION Registry includes annually followed adult patients with positive aPL based on the Revised Sapporo Classification Criteria. We analyzed baseline and prospective core laboratory data of the registry for associations among aPL tests using the Spearman rank correlation with Bonferroni-adjusted significance level for multiple comparisons. An aPL Load was calculated based on 6 tests (aCL IgG/IgM/IgA and aβ2GPI IgG/IgM/IgA); a receiver operating characteristic curve was used to evaluate the diagnostic performance of the aPL Load in predicting LA positivity. In 351 patients simultaneously tested for LA, aCL, and aβ2GPI, the frequency of moderate-to-high (≥40 U) titers of aCL and aβ2GPI IgG/IgM/IgA was higher in patients who were positive for LA vs those who were negative. An aPL Load was calculated for each patient to assess the overall aPL burden. For every 1-point increase in the aPL Load, the possibility of a positive LA test increased by 32% (odds ratio, 1.32; 95% CI, 1.2-1.5; P <.001). Based on core laboratory data from a large international registry, most aPL enzyme-linked immunosorbent assay ≥40 U and a high calculated aPL Load combining 6 aPL enzyme-linked immunosorbent assays were predictive of a positive LA. These data suggest that the combined quantitative burden of aPL may provide a mechanistic explanation of a positive LA.
anticardiolipin; antiphospholipid antibodies; antiphospholipid syndrome; lupus anticoagulant
Settore MEDS-09/C - Reumatologia
giu-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
Efthymiou_Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers_AAM.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Licenza: Creative commons
Dimensione 427.83 kB
Formato Adobe PDF
427.83 kB Adobe PDF Visualizza/Apri
1-s2.0-S0023683723000909-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1185756
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
  • OpenAlex 7
social impact